What changed in Abbott Laboratories's latest annual report
In the year ended 31 Dec 2025, Abbott Laboratories's revenue rose 5.7% to USD 44.33bn, from USD 41.95bn; net income fell 51.3% to USD 6.52bn, from USD 13.40bn; long-term debt fell 21.6% to USD 9.90bn, from USD 12.62bn.
Year ended 31 Dec 2025. Source: 10-K filed 20 Feb 2026, read it on SEC EDGAR.
USD 41.95bn to USD 44.33bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 41.95bn | 44.33bn | Up 5.7% |
| Net income | 13.40bn | 6.52bn | Down 51.3% |
| Total assets | 81.41bn | 86.71bn | Up 6.5% |
| Long-term debt | 12.63bn | 9.90bn | Down 21.6% |
| Cash and cash equivalents | 7.62bn | 8.52bn | Up 11.9% |
| Shareholders' equity | 47.66bn | 52.13bn | Up 9.4% |
Questions people ask
Did Abbott Laboratories's revenue grow last year?
Revenue grew 5.7%, from USD 41.95bn to USD 44.33bn in the year ended 31 Dec 2025.
Is Abbott Laboratories profitable?
Yes. Net income was USD 6.52bn in the year ended 31 Dec 2025. The year before: USD 13.40bn.
How much cash and debt does Abbott Laboratories have?
At its latest year end (31 Dec 2025), Abbott Laboratories reported cash and cash equivalents of USD 8.52bn and long-term debt of USD 9.90bn.
Where do these numbers come from?
From Abbott Laboratories's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Abbott Laboratories?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%
- Regeneron Pharmaceuticals, Inc.Cash and cash equivalents up 25.3%